Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
31 Oct 2016 NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Oct 2016 FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
27 Oct 2016 EMA Recommends a Change to the Terms of the Marketing Authorisation for Arsenic Trioxide Haematologic malignancies - Anticancer agents & Biologic therapy
26 Oct 2016 Off-Label Drug Coverage in Oncology Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Grants Accelerated Approval to New Treatment for Advanced STS Sarcomas - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Modifies Indication for Erlotinib in NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Oct 2016 2016 Nobel Prize in Physiology or Medicine Basic science
20 Oct 2016 FDA Approves Atezolizumab for Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
19 Oct 2016 EMA Adopts a New Indication for Nivolumab Haematologic malignancies - Cancer Immunology and Immunotherapy
18 Oct 2016 Withdrawal of the Marketing Authorisation Application for Cediranib Gynaecologic malignancies - Anticancer agents & Biologic therapy
17 Oct 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Venetoclax Haematologic malignancies - Anticancer agents & Biologic therapy
10 Oct 2016 ESMO 2016 Press Release: Longer Disease-free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016: The NETwork! Translational Programme Facilitates Genomic Analysis of Neuroendocrine Tumours Translational research - Endocrine and neuroendocrine tumours
10 Oct 2016 ESMO 2016: Metformin Significantly Lowers the Risk of Cancer Progression in Patients with Diabetes and Advanced pNETs Endocrine and neuroendocrine tumours - Anticancer agents & Biologic therapy
10 Oct 2016 ESMO 2016: Clinical Benefit Demonstrated with Everolimus and Pasireotide LAR Alone or in Combination in the First Randomised, Prospective Study Entirely Dedicated to Advanced Lung and Thymic Carcinoids Endocrine and neuroendocrine tumours - Anticancer agents & Biologic therapy